Prediction, Prevention of Ovarian Cancer Metastasis Has New Developments

Share this content:

the Cancer Therapy Advisor take:

Previously, scientists thought that ovarian cancer spreads through direct surface contact with adjacent organs located in the abdominal cavity. According to a study published in the journal Cancer Cell, researchers discovered that ovarian cancer spreads through tumor cells circulating through the bloodstream. Once these tumor cells target fatty tissue, they grow and spread to other organs.


Senior author Anil Sood, MD, and colleagues at The University of Texas MD Anderson Cancer Center found that the circulating tumor cells navigate to the omentum, a fatty tissue that supports and covers abdominal organs, by relying on the receptor protein HER3. This protein is similar to its HER2 counterpart that is present in some breast cancers. Novel therapeutic options may be developed to target HER3’s significant presence, which may be a biomarker for ovarian cancer metastasis.


Researchers found that when the tumors expressed a higher amount of the protein, survival decreased. In their study, 11 patients with ovarian cancer and found that their cells were 90% HER3-positive. These patients had a survival of 3.15 years, which was comparatively lower than the 4.9 years of patients with lower HER3 expression levels. In addition, researchers discovered that the bonding ligand NRG1 causes ovarian cancer’s dependency on HER3.

Prediction, Prevention of Ovarian Cancer Metastasis Has New Developments
Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists at The University of Texas MD Anderson Cancer Center report in Cancer Cell.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs